Home Alzheimer’s Disease Optimal Number of Treatment Courses Explored in Younger Patients with AML

Optimal Number of Treatment Courses Explored in Younger Patients with AML

A study of the optimal number of treatment courses of high-dose daunorubicin and cytarabine (Ara-C) for younger patients with acute myeloid leukemia (AML) published in the Journal of Clinical Oncology revealed that although a fourth course reduced cumulative incidence of relapse (CIR) and improved relapse-free survival (RFS), it did not result in a significant overall survival (OS) benefit.1

However, even with this knowledge, the investigators suggested that if Ara-C is the selected consolidation treatment, a fourth course of overall treatment would likely be beneficial.

“In general, patients with more favorable characteristics appear to benefit from a fourth course, but only when high-dose Ara-C consolidation is used, whereas those with intermediate-risk characteristics do not, although these were only trends for benefit,” explained the study authors, who were led by Alan K….

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments